Meridian Wealth Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Meridian Wealth Management's AXSM Position: Q3 2026 in Review
Meridian Wealth Management increased its Axsome Therapeutics (AXSM) stake by 2.8% in Q3 2026, buying an estimated $132K and bringing the position to 22,636 shares worth $4.17M. The position accounts for 0.12% of the portfolio, ranked #157.
Meridian Wealth Management first reported a position in AXSM in Q2 2022 and has held it in 17 quarters since. The position peaked at $5.39M in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Meridian Wealth Management held 22,636 shares of Axsome Therapeutics worth $4.17M as of Q3 2026.
- Meridian Wealth Management bought 608 Axsome Therapeutics shares in Q3 2026, an estimated $132K.
- Axsome Therapeutics made up 0.12% of Meridian Wealth Management's portfolio in Q3 2026, its #157 holding.
- Meridian Wealth Management first reported a position in Axsome Therapeutics in Q2 2022 and has held it in 17 quarters since.
- Meridian Wealth Management's Axsome Therapeutics position peaked at $5.39M in Q2 2026.
- 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Meridian Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.